CATABASIS PHARMACEUTICALS, INC. ONE KENDALL SQUARE BUILDING 1400E, SUITE B14202 CAMBRIDGE, MA 02139

June 19, 2018

Via EDGAR

Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

Re: Catabasis Pharmaceuticals, Inc.

Registration Statement on Form S-1

File No. 333-225410 Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Catabasis Pharmaceuticals, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-225410), so that it may become effective at 5:00 p.m. Eastern time on June 19, 2018, or as soon thereafter as practicable.

[The remainder of this page is intentionally left blank.]

Very truly yours,

Catabasis Pharmaceuticals, Inc.

By: /s/ Deirdre A. Cunnane
Name: Deirdre A. Cunnane

Title: Chief Legal Officer

[Signature Page to Request for Acceleration]